07:56 AM EDT, 05/05/2025 (MT Newswires) -- Teva Pharmaceutical (TEVA) and Alvotech ( ALVO ) said Monday that Selarsdi has been approved by the US Food and Drug administration as interchangeable with the reference biologic Stelara.

Selarsdi, a human monoclonal antibody that selectively targets the p40 protein, is now interchangeable in all presentations of Stelara, which includes the treatment of psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis, the two companies said.

Teva shares were more than 7% higher in premarket trading, while Alvotech ( ALVO ) shares rose by nearly 2%.